Prostate cancer vaccines update on clinical development

OncoImmunology

Volumn 2, Issue 5, 2013, Pages

  Geary, Sean M ^a   Salem, Aliasger K ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Cell based prostate cancer vaccines; Clinical trials; DNA Vaccines; Gene mediated cytotoxic immunotherapy; GVAX PCa; Prostate cancer; ProstVac VF; Sipuleucil T; Viral based prostate cancer vaccines

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; CANCER VACCINE; DNA VACCINE; GELFOAM; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INTERLEUKIN 2; IPILIMUMAB; NIVOLUMAB; PLACEBO; PROSTATE SPECIFIC ANTIGEN; RILIMOGENE GALVACIREPVEC; SIPULEUCEL T; THYMIDINE KINASE; VIRUS VECTOR;

ADENOVIRUS 5; ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; ARTHROPATHY; ARTICLE; AUTOIMMUNE DISEASE; CANCER FATIGUE; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; COLITIS; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPOPHYSITIS; IMMUNE RESPONSE; INJECTION SITE REACTION; LOW DRUG DOSE; LUNG ALVEOLITIS; LUNG SARCOIDOSIS; MELANOMA; METASTASIS; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; SURVIVAL RATE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

EID: 84885659813     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.24523     Document Type: Article

References (74)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29; PMID:22237781; http://dx.doi.org/10.3322/caac.20138
2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46:765-81; PMID:20116997; http://dx.doi.org/10.1016/j.ejca.2009.12.014
3. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011; 65:1180-92; PMID:21995694; http://dx.doi.org/10.1111/j.1742-1241.2011.02799.x
4. Inoue T, Segawa T, Kamba T, Yoshimura K, Nakamura E, Nishiyama H, et al. Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan. Urology 2009; 73:1104-9; PMID:19394511; http://dx.doi. org/10.1016/j.urology.2008.07.062
5. Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005; 23:2918-25; PMID:15860850; http://dx.doi.org/10.1200/JCO.2005.01.529
6. Beltran H, Beer TM, Carducci MA, De Bono J, Gleave M, Hussain M, et al. New therapies for castrationresistant prostate cancer: efficacy and safety. Eur Urol 2011; 60:279-90; PMID:21592649; http://dx.doi. org/10.1016/j.eururo.2011.04.038
7. Coffey DS, Isaacs JT. Prostate tumor biology and cell kinetics--theory. Urology 1981; 17(Suppl 3):40-53; PMID:7010755
8. Kiessling A, Fssel S, Wehner R, Bachmann M, Wirth MP, Rieber EP, et al. Advances in specific immunotherapy for prostate cancer. Eur Urol 2008.53:694-708; PMID:18061335; http://dx.doi.org/10.1016/j. eururo.2007.11.043
9. Burch PA, Breen JK, Buckner JC, Gastineau DA, Kaur JA, Laus RL, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000; 6:2175-82; PMID:10873066
10. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18:3894-903; PMID:11099318
11. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel- T in advanced prostate cancer. Cancer 2009; 115:3670-9; PMID:19536890; http://dx.doi.org/10.1002/cncr.24429
12. KantoffPW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al.; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294
13. Sonpavde G, Di Lorenzo G, Higano CS, KantoffPW, Madan R, Shore ND. The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. Eur Urol 2012; 61:639-47; PMID:22036643; http://dx.doi.org/10.1016/j. eururo.2011.10.027
14. Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 2010; 10:580-93; PMID:20651745; http://dx.doi.org/10.1038/nri2817
15. Geary SM, Lemke CD, LubaroffDM, Salem AK. Proposed mechanisms of action for prostate cancer vaccines. Nat Rev Urol 2013; 10:149-60; PMID:23399727; http://dx.doi.org/10.1038/nrurol. 2013.8
16. Huber ML, Haynes L, Parker C, Iversen P. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst 2012; 104:273-9; PMID:22232132; http://dx.doi.org/10.1093/jnci/djr514
17. Drake CG. Re: interdisciplinary critique of sipuleucel- T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst 2012; 104:1422, author reply 1422-3; PMID:22911668; http://dx.doi. org/10.1093/jnci/djs340
18. Gulley JL, Leitman SF, Dahut W, Schlom J. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst 2012; 104:1106, author reply 1109-12; PMID:22825555; http://dx.doi.org/10.1093/jnci/djs280
19. Arlen PM, Skarupa L, Pazdur M, Seetharam M, Tsang KY, Grosenbach DW, et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol 2007; 178:1515-20; PMID:17707059; http://dx.doi. org/10.1016/j.juro.2007.05.117
20. DiPaola RS, Plante M, Kaufman H, Petrylak DP, Israeli R, Lattime E, et al. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med 2006; 4:1; PMID:16390546; http://dx.doi.org/10.1186/1479-5876-4-1
21. KantoffPW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28:1099-105; PMID:20100959; http://dx.doi. org/10.1200/JCO.2009.25.0597
22. Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 2010; 59:663-74; PMID:19890632; http://dx.doi. org/10.1007/s00262-009-0782-8
23. Higano C, Saad F, Somer B, Curti B, Petrylak DP, Drake CG, et al. A phase III trial of GVAX immunotherapy for prostate cancer vs. docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). Genitourinary Cancer Symposium: Proc Am Soc Clin Oncol, 2009:Abstract # LBA150
24. Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006:12:1260-9 PMID:16489082:http://dx.doi.org/10.1158/1078-0432.CCR-05-2059
25. LubaroffDM, Konety BR, Link B, Gerstbrein J, Madsen T, Shannon M, et al. Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin Cancer Res 2009; 15:7375-80; PMID:19920098; http://dx.doi.org/10.1158/1078-0432.CCR-09-1910
26. Small EJ, Sacks N, Nemunaitis J, Urba WJ, Dula E, Centeno AS, et al. Granulocyte macrophage colonystimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 2007; 13:3883-91; PMID:17606721; http://dx.doi.org/10.1158/1078-0432.CCR-06-2937
27. Higano CS, Corman JM, Smith DC, Centeno AS, Steidle CP, Gittleman M, et al. Phase 1/2 doseescalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormonerefractory prostate cancer. Cancer 2008; 113:975-84; PMID:18646045; http://dx.doi.org/10.1002/cncr.23669
28. Small EJDT. Gerritsen WR, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). 2009 Genitourinary Cancers Symposium (ASCO Annual Meeting Abstracts) 2009:LBA150
29. Van den Eertwegh AJ, Versluis J, Van den Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13:509-17; PMID:22326922; http://dx.doi.org/10.1016/S1470-2045(12)70007-4
30. McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 2009; 27:4047-54; PMID:19636017; http://dx.doi. org/10.1200/JCO.2008.19.9968
31. Pavlenko M, Roos AK, Lundqvist A, Palmborg A, Miller AM, Ozenci V, et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 2004; 91:688-94; PMID:15280930
32. Herman JR, Adler HL, Aguilar-Cordova E, Rojas-Martinez A, Woo S, Timme TL, et al. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther 1999; 10:1239-49; PMID:10340555; http://dx.doi. org/10.1089/10430349950018229
33. Miles BJ, Shalev M, Aguilar-Cordova E, Timme TL, Lee HM, Yang G, et al. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther 2001; 12:1955-67; PMID:11686937; http://dx.doi.org/10.1089/104303401753204535
34. Ayala G, Satoh T, Li R, Shalev M, Gdor Y, Aguilar-Cordova E, et al. Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther 2006; 13:716-28; PMID:16480930; http://dx.doi.org/10.1016/j.ymthe.2005.11.022
35. Fong L, Weinberg VK, Corman JM, Amling CL, Stephenson RA, Formaker C, et al. Immune responses in prostate tumor tissue following neoadjuvant sipuleucel- T in patients with localized prostate cancer. 2012 Genitiurinary Cancers Symposium. J Clin Oncol 2012
36. Le DT, Pardoll DM, Jaffee EM. Cellular vaccine approaches. Cancer J 2010; 16:304-10; PMID:20693840; http://dx.doi.org/10.1097/PPO.0b013e3181eb33d7
37. Van den Eertwegh AJ, Versluis J, Van den Berg HP, Santegoets SJ, van Moorselaar RJ, Van der Sluis TM, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13:509-17; PMID:22326922; http://dx.doi.org/10.1016/S1470-2045(12)70007-4
38. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999; 190:355-66; PMID:10430624; http://dx.doi. org/10.1084/jem.190.3.355
39. Hurwitz AA, Yu TF, Leach DR, Allison JP. CTLA-4 blockade synergizes with tumor-derived granulocytemacrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A 1998; 95:10067-71; PMID:9707601; http://dx.doi.org/10.1073/pnas.95.17.10067
40. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
41. Robert C, Thomas L, Bondarenko I, O'Day S, M D JW, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621
42. Small E, Demkow T, Gerritsen W, Rolland F, Hoskin P, Smith D, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel vs. docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). Genitourinary Cancer Symposium: Proc Am Soc Clin Oncol 2009:Abstract #7
43. Drake CG. Immunotherapy for prostate cancer: walk, don't run. J Clin Oncol 2009; 27:4035-7; PMID:19635998; http://dx.doi.org/10.1200/JCO.2009.22.2299
44. Kaufman HL, Wang W, Manola J, DiPaola RS, Ko YJ, Sweeney C, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2004; 22:2122-32; PMID:15169798; http://dx.doi.org/10.1200/JCO.2004.08.083
45. Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 2002; 53:109-17; PMID:12242725; http://dx.doi.org/10.1002/pros.10130
46. Halabi S, Small EJ, KantoffPW, Kattan MW, Kaplan EB, Dawson NA, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21:1232-7; PMID:12663709; http://dx.doi.org/10.1200/JCO.2003.06.100
47. Gulley JL, Madan RA, Schlom J. Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr Oncol 2011; 18:e150-7; PMID:21655153; http://dx.doi.org/10.3747/co.v18i3.783
48. Gulley JL, Madan RA, Stein WD, Wilkerson J, Dahut WL, Heery CR, et al. Effect of PSA-tricom, a pox-viral vaccine in prostate cancer (PCa), on tumor growth rates within 80 days after initiation in nonmetastatic PCa. Genitourinary Cancer Symposium: J Clin Oncol 2013:suppl 6:abstract #57
49. Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, et al. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 2008; 105:14987-92; PMID:18818309; http://dx.doi.org/10.1073/pnas.0806075105
50. Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13:501-8; PMID:22326924; http://dx.doi.org/10.1016/S1470-2045(12)70006-2
51. Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen- 4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005; 23:741-50; PMID:15613700; http://dx.doi. org/10.1200/JCO.2005.01.128
52. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte- associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003; 100:8372-7; PMID:12826605; http://dx.doi. org/10.1073/pnas.1533209100
53. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23:6043-53; PMID:16087944; http://dx.doi.org/10.1200/JCO.2005.06.205
54. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28:3167-75; PMID:20516446; http://dx.doi. org/10.1200/JCO.2009.26.7609
55. Andersen MH, Junker N, Ellebaek E, Svane IM, Thor Straten P. Therapeutic cancer vaccines in combination with conventional therapy. J Biomed Biotechnol 2010; 2010:237623; PMID:20617155; http://dx.doi. org/10.1155/2010/237623
56. Schlom J. Recent advances in therapeutic cancer vaccines. Cancer Biother Radiopharm 2012; 27:2-5; PMID:22251077; http://dx.doi.org/10.1089/cbr.2012.1200
57. Liniger M, Zuniga A, Naim HY. Use of viral vectors for the development of vaccines. Expert Rev Vaccines 2007; 6:255-66; PMID:17408374; http://dx.doi. org/10.1586/14760584.6.2.255
58. Cheng C, Gall JG, Kong WP, Sheets RL, Gomez PL, King CR, et al. Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells. PLoS Pathog 2007; 3:e25; PMID:17319743; http://dx.doi.org/10.1371/journal.ppat.0030025
59. Miller G, Lahrs S, Pillarisetty VG, Shah AB, DeMatteo RP. Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection. Cancer Res 2002; 62:5260-6; PMID:12234994
60. Siemens DR, Elzey BD, LubaroffDM, Bohlken C, Jensen RJ, Swanson AK, et al. Cutting edge: restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix. J Immunol 2001; 166:731-5; PMID:11145643
61. LubaroffDM, Konety B, Link BK, RatliffTL, Madsen T, Shannon M, et al. Clinical protocol: phase I study of an adenovirus/prostate-specific antigen vaccine in men with metastatic prostate cancer. Hum Gene Ther 2006; 17:220-9; PMID:16454655; http://dx.doi. org/10.1089/hum.2006.17.220
62. LubaroffDM. Prostate cancer vaccines in clinical trials. Expert Rev Vaccines 2012; 11:857-68; PMID:22913261; http://dx.doi.org/10.1586/erv.12.54
63. LubaroffDM, Williams RD, Vaena D, Joudi F, Brown J, Smith M, et al. An ongoing Phase II trial of an adenovirus/PSA vaccine for prostate cancer. 103rd Annual Meeting of the American Association for Cancer Research. Chicago IL: Cancer Res, 2012
64. Ahmad S, Sweeney P, Sullivan GC, Tangney M. DNA vaccination for prostate cancer, from preclinical to clinical trials - where we stand? Genet Vaccines Ther 2012; 10:9; PMID:23046944; http://dx.doi. org/10.1186/1479-0556-10-9
65. Becker JT, Olson BM, Johnson LE, Davies JG, Dunphy EJ, McNeel DG. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother 2010; 33:639-47; PMID:20551832; http://dx.doi. org/10.1097/CJI.0b013e3181dda23e
66. Roos AK, Pavlenko M, Charo J, Egevad L, Pisa P. Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine. Prostate 2005; 62:217-23; PMID:15389792; http://dx.doi. org/10.1002/pros.20135
67. Roos AK, Moreno S, Leder C, Pavlenko M, King A, Pisa P. Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation. Mol Ther 2006; 13:320-7; PMID:16185933; http://dx.doi.org/10.1016/j.ymthe.2005.08.005
68. Fyfe JA, Keller PM, Furman PA, Miller RL, Elion GB. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl) guanine. J Biol Chem 1978; 253:8721-7; PMID:214430
69. Eastham JA, Chen SH, Sehgal I, Yang G, Timme TL, Hall SJ, et al. Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum Gene Ther 1996; 7:515-23; PMID:8800746; http://dx.doi.org/10.1089/hum.1996.7.4-515
70. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, et al. The bystander effect: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53:5274-83; PMID:8221662
71. Aguilar LK, Guzik BW, Aguilar-Cordova E. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development. J Cell Biochem 2011; 112:1969-77; PMID:21465529; http://dx.doi.org/10.1002/jcb.23126
72. Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, et al. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys 2004; 58:1520-9; PMID:15050332; http://dx.doi. org/10.1016/j.ijrobp.2003.09.083
73. Senovilla L, Garcia P, Eggermont A, Fridman WH, Galon J, Zitvogel L, et al. Trial watch: DNA vaccines for cancer therapy. OncoImmunology 2013; 2:e23803; http://dx.doi.org/10.4161/onci.23803
74. Teh BS, Aguilar-Cordova E, Kernen K, Chou CC, Shalev M, Vlachaki MT, et al. Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report. Int J Radiat Oncol Biol Phys 2001; 51:605-13; PMID:11597799; http://dx.doi.org/10.1016/S0360-3016(01)01692-3